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ABSTRACT  
“Personalised medicine” is currently attracting considerable attention and raising high 
hopes and expectations in modern medicine. The term “personalised medicine” denotes the 
use of genetic or other biomarker information, and it does not focus on a more personal 
patient-doctor relationship. Furthermore, personalised medicine is associated with ethical 
problems like priority setting and opportunity costs in solidarity-based public health care 
systems. Personalised medicine provides modern, highly specific and expensive diagnostics 
and treatments, which serve only limited subgroups of patients. At the same time, research in 
other fields of clinical medicine, which could be of benefit to more patients than such limited 
subgroups, remain underfunded.
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Introduction
Modern medicine now has access to extensive genetic information about humans. 
In the international Human Genome Project the entire human genome was decoded, 
and technical progress in the field of sequencing technologies enables inexpensive 
analyses of the complete genome of an individual. Clinical medicine is seeking to 
utilise these insights from molecular genetics research to treat patients more 
effectively. In the field of medical diagnostics and treatment, knowledge about the 
individual genes of a patient is being used to develop custom-tailored, individualised 
treatments (Chin et al. 2011; McDermott et al. 2011; Phimister et al. 2012; Sledge 
2012). For instance, by determining specific genetic biomarkers in a patient prior to 
starting treatment, doctors can determine whether or not a cancer drug will be 
effective against a specific tumour. Ineffective treatments can be excluded from the 
outset, and patients can therefore also be spared unnecessary adverse side effects. 
Furthermore, the pharmaceutical industry contends that by avoiding ineffective 
treatments, considerable health care costs can be saved (Richter-Kuhlmann 2012a).
This concept of personalised medicine is not only often used in oncology, but also 
raises hopes of successful treatments for other common diseases, such as 
cardiovascular diseases, type 2 diabetes mellitus and mental disorders. Frequently, 
personalised medicine is used as a synonym for progress and the promise of modern 
medicine per se and is presented in an uncritically positive way in research, business 
and the media (Collins 2011; Holsboer 2011; Schwan 2013). Public research 
funding has declared personalised medicine to be a priority both at the European 
and also at the national level (Bundesministerium für Bildung und Forschung 
2010), and large pharmaceutical and biotechnology companies invest billions of 
euros into this research. Due to new scientific insights and the close cooperation of 
research, clinics and industry (Collins 2011; Hüsing 2010; Mirnezami et al. 2012), 
modern medicine is facing a new “revolution” (Richter-Kuhlmann 2012a). The 
treatment concept also appeals to medical laypersons, as something that is worthy of 
support. However, are the hopes associated with personalised medicine well-
founded, and are the high investments justified?
The concept of a person and “personalised medicine”
The term “personalised medicine” insinuates a kind of medical care which focuses 
on the health situation and the particular needs of each individual person. This is 
incorrect and misleading in two ways. First, the molecular genetic complexity of 
many illnesses makes the possibility of a treatment custom-tailored to each 
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individual person very improbable, while the extremely high efforts and costs of this 
approach do not appear feasible in the current health care system. What the term 
connotes is therefore not personalised diagnosis and treatment but at best diagnostic 
and therapeutic approaches which are targeted at specific patient subgroups, for 
example, groups which have the same tumour biomarkers (stratified medicine). 
Second, medical care focused on molecular genetic characteristics has nothing to do 
with medical care oriented on the individual patient. Individualisation only takes 
place at the molecular genetic level, but not at the personal level between doctor 
and patient. To achieve a personal treatment, the person of the patient should be 
placed at the centre of treatment, and this is exactly what so-called personalised 
medicine does not do (Dabrock et al. 2012; Hüsing 2010). A person is not only 
distinguished by biological traits, but also by individual psychological and social 
characteristics and needs. Individuals have their own lifestyles, values and 
preferences (Yurkiewicz 2010). Law and ethics emphasise the normative implications 
of the concept of personhood, as evident in ongoing debates about so-called 
“personhood” (Lampe 1998; Mahowald 1995). As a consequence, in the doctor-
patient relationship the patient is entitled to adequate education and information 
by the doctor and has the individual right to consent to or to refuse a treatment 
(Kohnen et al. 2012). The patient’s self-determined decision must be respected, 
even if it goes against the doctor’s advice and against a medical indication, precisely 
because we ascribe the person these rights (Vollmann 2008). 
This ethical and anthropological understanding of the “person” is expressed by many 
people in their wishes towards modern medicine. Patients wish to be perceived by 
their doctors and by medical institutions as individual persons with questions, 
wishes and normative preferences. In the citizens’ report “High-Tech Medicine – 
What Kind of Health Care Do We Want?“ of the German Federal Ministry of 
Education and Research, citizens demand that medical and nursing staff have better 
communication skills. Furthermore, alongside the specialist subjects, mental and 
interpersonal aspects in day-to-day patient care must play an equal role in medical 
and nursing education and training and in research. The importance of taking time 
for the patient should be rediscovered in modern medicine ((Bundesministerium 
für Bildung und Forschung 2011; cf. also (Koch 2012; Siegmund-Schultze 2011)). 
This broader cultural understanding of the term “person” and the wishes of citizens 
for personal medical care are not considered in so-called personalised medicine. The 
term sounds appealing but is misleading. The intention of the inappropriate use of 
the term “person”, which is conveyed in numerous texts and images in advertising 
materials, is to achieve a positive image and wide acceptance in society. It is 
important to debunk this questionable advertising strategy because it abuses the 
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concept of personhood, perceives patients primarily as carriers of molecular 
genetically determined traits, suggests a genetic determinism for medicine (Kerr 
und Cunningham-Burley 2000; Tauber und Sarkar 1993) and aims at setting 
specific priorities in research funding. The latter, in particular, requires a transparent 
and critical discussion, as well as democratic decision-making.
Basic research and clinical application
Additional doubts arise with regard to the statement of the U.S. Food and Drug 
Administration (FDA) that after a decade of billions of dollars in investments in the 
Human Genome Project and in subsequent genetic analysis studies, the yield has only 
been a small number of clinical treatments on the basis of genetic biomarkers 
(Hüsing 2010; Marshall 2011). In addition, for the president of the Max Planck 
Society, the hope of immediately deriving rapid medical progress from the 
deciphering of the human genome has hardly been fulfilled (Gruss 2011). Upon 
closer scientific observation the reason for this discrepancy is clear. The clinical 
applications that have been successful until now are mainly in the field of oncology 
and are limited to a few tumour types for which the molecular genetic biomarkers 
are known and for which there is a treatment available. This fortunate constellation 
is the exception in clinical practice; for the majority of patients these new treatments 
are of no benefit. The scientific explanation for the slow clinical progress lies in the 
complexity of tumour biology, where the variability and mutation dynamics of the 
genetic traits of many tumours complicate the development of targeted therapies. 
Progress in clinical treatment and practice does not necessarily follow from a 
brilliant treatment approach that is derived from basic research (Browman et al. 
2011; Burke und Psaty 2007; Konstantinopoulos et al. 2009; Ludwig 2012). 
Unfortunately, the international experience during the last decade makes rapid 
clinical progress for the majority of cancer patients very unlikely.
Medical research and industry under pressure to succeed
This sobering conclusion is contrary to the euphoria about the promise of 
personalised medicine. After decades without innovation breakthroughs, many 
biomedical researchers long for significant therapeutic progress (Collins 2011; 
Holsboer 2011; Hudson 2009). The pharmaceutical industry is in a similar situation 
– its patents for the strongest selling drugs (so-called “blockbusters”) are due to 
expire in the coming years, and many companies do not have any new innovative 
drugs in their development pipeline (Collier 2011; Greiner 2012). Rather, the 
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pharmaceutical and biotechnology industries are under pressure from the markets 
to reduce their high costs for research and development, since these, given the lack 
of innovation, do not refinance themselves (Aiolfi 2011; Dhankhar et al. 2012; 
Hunt et al. 2011; KPMG 2011). Compared to the stock price development of other 
companies, the value of many pharmaceutical companies has declined, while the 
return on investment from the high expenditures in research and development has 
been falling for years. As a result, consultants predict tough times ahead for the 
pharmaceutical industry (Frankfurter Allgemeine Zeitung 2012). 
In this difficult economic situation, many pharmaceutical companies are counting 
on rapid progress in the new field of personalised medicine. However, the high 
expectations are contrasted by the sluggish progress in the clinical application of 
personalised medicine (Ludwig 2012). In practice, there is a danger that 
insufficiently tested drugs might be introduced too hastily into clinical care. New 
“personalised” diagnostics and therapeutics may not have been approved without 
sufficient proof of their effectiveness. However, validation studies that are required 
for scientific proof of effectiveness are seldom carried out because these are long-
term, complex and costly (Ludwig 2012). It is commonly argued that, in 
personalised medicine, the relevant cost and time-consuming proof of effectiveness 
does not apply and should be abbreviated to get approval for the drug. But even in 
small patient groups and targeted treatments, the effectiveness and benefit of new 
drugs must be scientifically proven to ensure the health and welfare of the patients 
and to avoid unnecessary health costs (Ludwig et al. 2009; Richter-Kuhlmann 
2012a). 
For this reason, drugs in the field of personalised treatments must be checked 
according to normal approval procedures, in order to meet scientific and therapeutic 
standards. Since current clinical research in the field of personalised medicine is 
primarily financed by the pharmaceutical industry, conflicts of interest are inevitable 
(Valachis et al. 2012). To promote the necessary gain in scientific knowledge in this 
new field, we therefore need more clinical research that is publically funded and is 
independent from the private sector. This would strengthen serious patient-oriented 
clinical research that is independent of short-term economic interests (Vollmann et 
al. 2011). At present, however, universities and other public research organisations 
in this field are hardly autonomous and independent, so that the content of research 
activities and research strategies are often heavily influenced by industry (Dreger 
2011).
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Priority setting and opportunity costs
The high investment costs in research based on molecular genetic criteria raise the 
question of opportunity costs. This type of research ultimately provides stratified 
medical care that only benefits subgroups of patients. Investments in this field have 
been made for more than a decade and, due to many open research questions, will 
continue to be made in the future (Rauprich 2010). Given the limited resources in 
the health care sector, a prioritisation decision is required already at the research 
level regarding the extent of public resources that shall flow into particular areas of 
the health care system. A research priority in one area limits the remaining research 
funds for other medical specialty areas. With regard to the promotion and funding 
of personalised medicine, this difficult normative and political decision is further 
exacerbated since there are only a relatively small number of patients who may 
benefit from these very expensive measures. That is why clinical physicians are 
concerned that through the prioritised promotion of personalised medicine, other 
important clinical and health care areas which might be beneficial for many patients 
will be neglected (Browman et al. 2011; Koch 2012; Ludwig 2012; Siegmund-
Schultze 2011). Thus far, only a minority of patients have benefited from this 
expensive, research- and economics-driven project of personalised medicine 
(Browman et al. 2011; Deutscher Ethikrat [German Ethics Council] 2012; 
Hamburg und Collins 2010). Based on previous experience, high profits can be 
expected from expensive cancer drugs for small patient groups (so-called “niche 
busters”), and therefore this approach continues to appear lucrative for the 
pharmaceutical industry, without taking into account the health needs of the 
majority of patients in our health care system. 
Whereas in oncology at least a small portion of patients have benefited from the 
innovations of personalised medicine, they have until now brought no benefit for 
patients in other social and medically important disease groups. For example, for 
the common disease type 2 diabetes, all molecular genetic descriptions of subgroups, 
biomarkers, etc. are not superior to the usual preventive, diagnostic and treatment 
options and do not improve the health situation of the affected patients (Schulze 
2011). Moreover, screening for type 2 diabetes does not offer any relevant 
advantages (Simmons et al. 2012). Rather, as our society ages, our nutrition, exercise 
and lifestyle play an increasingly crucial role in the prevention and treatment of type 
2 diabetes (Kurth 2012; Richter-Kuhlmann 2012b). For this disease, modern 
medicine does not primarily require new molecular genetic insights but rather 
socio-medical care approaches and intensive public health research to enable and 
support at-risk and affected people to adopt healthy behaviours as individuals. But 
this research is seriously underfunded in our health care system. 
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Another example is the increasing importance of mental illness as a public health 
concern in our society. Mental illness and its treatment and prevention is of great 
significance for affected patients, health insurance companies, pension fund 
insurance companies who bear the cost for rehabilitation and for the labour market. 
According to the German Federal Ministry of Labour and Social Affairs, the missed 
days at work due to mental disorders have increased from 6.6% in 2001 to 13.1% 
in 2010, which is associated with economic costs of approximately EUR 8 - 10 
billion annually. The most important specified causes are higher demands at the 
workplace, increased personal responsibility, pressure to be flexible, irregular 
employment relationships and job insecurity (Deutsches Ärzteblatt 2012). The 
current care of these patients in our health care system is under criticism due to 
excessively long sick leave times, also excessive waiting times for psychiatric and 
psychotherapy treatment and/or inpatient rehabilitation measures, and too frequent 
early retirements due to mental disorders. Investments are therefore required in 
research to develop new concepts for social-psychiatric prevention and treatment, 
thus, for example, enabling effective prevention and early intervention at the 
workplace and improving the cooperation between the company doctor, primary 
care physician, psychiatrist and hospital, etc. This raises the issue whether we as a 
society shall respond to the increasing importance of mental illness primarily with 
high investments in molecular genetic research for “personalised treatment” or 
invest at least in equal measure in social psychiatric and mental health research, 
which in current research policy is allocated relatively few funds.
Therefore, from a medical ethics perspective, the existing preference for molecular 
genetics medicine in personalised medicine in contrast to other research fields in the 
publically funded health care system needs to be critically examined. In essence, all 
prioritisation decisions are ethical decisions in which competing values must be 
weighed (Rauprich 2010). In doing so, transparency must prevail regarding who 
decides about what facts, which criteria are used and on which arguments decisions 
are based. Therefore, it is ethically unacceptable that influential individual interests 
de facto determine medical research priorities and resource allocation in the 
publiclaly funded health care system. But this is exactly what is currently happening 
under the innocuous label of “personalised medicine”. Cost-benefit assessments of 
the individual treatments – now often discussed – are also insufficient, since, on the 
basis of empirical data, they only allow statements about the medical benefits and 
the costs of the treatment area under investigation. Frequently in practice, the 
selection of the treatment area for research already represents a setting of priorities 
within the overall spectrum of possible health-promoting measures, without prior 
reflection on the norms involved. For our health care in the future, what is required 
262
JAHR  Vol. 6/2  No. 12  2015
are transparent and democratically legitimised superordinate medical and research 
policy prioritisations. 
However, our society leaves crucial research policy decisions to internationally active 
stakeholders from research and industry. Whereas public funds have invested heavily 
in basic research (e.g. Human Genome Project), in the field of clinical applications 
priority setting is left to the discretion of international pharmaceutical industry. In 
Germany, universities and other public research organisations have little influence 
on content prioritisation in this field because, as I noted above, due to the lack of 
public funding, independent research hardly exists. To be sure, cooperation with the 
public health authorities is always emphasised in order to coordinate health care and 
socio-economic priorities. In reality, however, this plays hardly a role. The reason is 
that international pharmaceutical companies develop diagnostics and drugs for the 
world market (Dhankhar et al. 2012; Frankfurter Allgemeine Zeitung 2013; Hunt 
et al. 2011; KPMG 2011; Schwan 2013). However, the health care needs and the 
financing of the health care systems differ greatly in the various countries. For 
example, the currently still largest health care market in the U.S., with its strong 
private sector orientation and a high proportion of citizens who lack medical 
insurance, differs greatly from European health care systems. The demographic 
trend of Western societies contrasts sharply to that of the economically emerging 
countries such as Brazil and India, with their high proportion of young people in 
the population and a growing, upwardly mobile middle class that finances its 
medical care privately (Agarwal et al. 2012). In these so-called emerging markets, the 
pharmaceutical industry in 2020 will proportionately make equivalent profits as in 
the currently largest pharmaceutical market, the U.S. (KPMG 2011). And these 
profits will originate from innovative products, including products in the fields of 
personalised medicine, which are expensive and have to be paid for privately (Griggs 
2009). By contrast, the importance of European health care markets for the 
development of new drugs is declining. 
Given the different socio-economic and health priorities, which vary from country 
to country, the research and development investments of the pharmaceutical 
industry will follow international market opportunities, which are not necessarily 
congruent with health care needs in Germany and other European countries. To 
provide optimal health care for our population, it is essential to develop our own 
strategic research and health care policy in the public health sector. To achieve this, 
those responsible for health and research policy must recognise the existing problems 
and put them forward for public debate. However, past experience with a public 
discussion about setting priorities and rationing in the health care system in 
Germany gives little cause for optimism. A wealthy, shrinking and ageing society 
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does not muster the strength to carry out a reform or to design its own public health 
system. Thus, society should not complain when global stakeholders set priorities 
under the lofty-sounding label of personalised medicine – priorities that do not 
correspond to the society’s own health care needs. 
Conclusion 
Genetic biomarker-based personalised medicine does not contribute to a more 
personal treatment of individual patients, in contrast to patient- or person-centred 
medical care. Subgroups of patients, e. g. in oncology, may have medical advantages 
from the present progress in personalised medicine, but it is unlikely that this will 
be the case for the overall majority of patients. The promise of less expensive health 
care through personalised medicine lacks any empirical evidence. Rather, based on 
past experience, an increase of costs is more likely.
A public debate is needed on priority setting in medical research and treatment and 
about how societies and public health systems can influence the development of the 
research agenda regarding future health care priorities. 
Acknowledgements:   
This study was conducted in the research network “Personalised Medicine in Oncology: 
an Interdisciplinary Study on Ethical, Medical, Economical and Legal Aspects” (Grant 
project number: 01 GP 1001A), which is supported by the German Federal Ministry of 
Education and Research (BMBF). 
REFERENCES
1. Agarwal, S; d’Almeida, J; Francis, T (2012) Capturing the Brazilian pharma opportunity. Global pharma 
companies are missing a chance to serve Brazil’s increasingly prosperous and growing middle class. 
McKinsey Quarterly March 2012:1-4
2. Aiolfi, S (2011) Die Pharmaforschung ist zu teuer. Investoren zeigen sich irritiert über einen 
offensichtlichen Mangel an Effizienz. Neue Zürcher Zeitung, 31.12.2011
3. Browman, G; Hébert, PC; Coutts, J (2011) Personalized medicine: a windfall for science, but what 
about patients? Canadian Medical Association Journal 183:E1277
4. Bundesministerium für Bildung und Forschung (2010) Ideen. Innovation. Wachstum - Hightech-
Strategie 2020 für Deutschland. Berlin: Bundesministerium für Bildung und Forschung
264
JAHR  Vol. 6/2  No. 12  2015
5. Bundesministerium für Bildung und Forschung (2011) Bürgerreport: Hightech-Medizin - Welche 
Gesundheit wollen wir? Berlin: Bundesministerium für Bildung und Forschung
6. Burke, W; Psaty, BM (2007) Personalized medicine in the era of genomics. Journal of the American 
Medical Association 298:1682-1684
7. Chin, L; Andersen, JN; Futreal, PA (2011) Cancer genomics: from discovery science to personalized 
medicine. Nature Medicine 17:297 - 303
8. Collier, R (2011) Bye, bye blockbusters, hello niche busters. Canadian Medical Association Journal 
183:E697-E698
9. Collins, FS (2011) Meine Gene - mein Leben. Heidelberg: Spektrum Akademischer Verlag
10. Dabrock, P; Braun, M; Ried, J (2012) Individualisierte Medizin: Ethische und gesellschaftliche 
Herausforderungen. Forum 27:209-213
11. Deutscher Ethikrat [German Ethics Council] (2012) Pressemitteilungen: Ethikrat rückt den Patienten in 
den Fokus der personalisierten Medizin. Berlin: Deutscher Ethikrat
12. Deutsches Ärzteblatt (2012) Krankschreibungen: Mehr Fehltage wegen psychischer Erkrankungen. 
Deutsches Ärzteblatt 109:A-948
13. Dhankhar, A; Evers, M; Møller, M (2012) Escaping the sword of Damocles: toward a new future for 
pharmaceutical R&D. Chicago: McKinsey & Company
14. Dreger, P (2011) Brief: Priorisierung in der Forschung. Deutsches Ärzteblatt 108:A-2286
15. Frankfurter Allgemeine Zeitung (2012) Im Gespräch: Thomas Strüngmann, Unternehmer und Investor 
in der Pharmabranche. Frankfurter Allgemeine Zeitung, 10.04.2012
16. Frankfurter Allgemeine Zeitung (2013) Sanofi schmerzt Patentauslauf. Gewinn des Pharmakonzerns 
könnte 2013 sinken. Frankfurter Allgemeine Zeitung, 08.02.2013
17. Greiner, W (2012) Ökonomische Herausforderungen der individualisierten Medizin. Forum 27:203-
208
18. Griggs, JJ (2009) Personalized medicine: a perk of privilege? Clinical Pharmacology & Therapeutics 
86:21-23
19. Gruss, P (2011) Der Faktor Mensch. MaxPlanckForschung 1:6-7
20. Hamburg, MA; Collins, FS (2010) The path to personalized medicine. New England Journal of 
Medicine 363(4):301-304
21. Holsboer, F (2011) Biologie für die Seele: Mein Weg zur personalisierten Medizin. München: dtv
22. Hudson, TJ (2009) Personalized medicine: a transformative approach is needed. Canadian Medical 
Association Journal 180:911-913
23. Hunt, V; Manson, N; Morgan, P (2011) A wake-up call for big pharma: pharmaceuticals & medical 
products practice. McKinsey Quarterly December 2011:1-6
24. Hüsing, B (2010) Individualisierte Medizin – Potenziale und Handlungsbedarf. Zeitschrift für Evidenz, 
Fortbildung und Qualität im Gesundheitswesen 104:727-731
25. Kerr, A; Cunningham-Burley, S (2000) On ambivalence and risk: reflexive modernity and the new 
human genetics. Sociology 34:283-304
26. Koch, M (2012) Arzt-Patienten-Beziehung: In falsches Fahrwasser geraten. Deutsches Ärzteblatt 109:A-
20
27. Kohnen, T; Schildmann, J; Vollmann, J (2012) Patients’ self-determination in “personalized medicine”: 
the case of whole genome sequencing and tissue banking in oncology, Individualized medicine between 
hype and hope. Hg. P Dabrock; M Braun; J Ried. Zürich: Lit Verlag, 97-110
28. Konstantinopoulos, PA; Karamouzis, MV; Papavassiliou, AG (2009) Educational and social-ethical 
issues in the pursuit of molecular medicine. Molecular Medicine 15:60-63
29. KPMG (2011) Pharmaceuticals: Future pharma. Five strategies to accelerate the transformation of the 
pharmaceutical industry by 2020. London: KPMG
Jochen Vollmann: Personalised medicine: Priority setting and opportunity costs in European public...  str. 255 – 266
265
30. Kurth, B-M (2012) Erste Ergebnisse aus der “Studie zur Gesundheit Erwachsener in Deutschland” 
(DEGS). Bundesgesundheitsblatt 55:980-990
31. Lampe, E-J (1998) Persönlichkeit, Persönlichkeitssphäre, Persönlichkeitsrecht, Persönlichkeit, Familie, 
Eigentum: Grundrechte aus der Sicht der Sozial- und Verhaltenswissenschaften. Hg. E-J Lampe. 
Opladen: Westdeutscher Verlag, 73-102
32. Ludwig, W-D; Fetscher, S; Schildmann, J (2009) Teure Innovationen in der Onkologie – für alle? 
Überlegungen zu Voraussetzungen für eine rationale Pharmakotherapie und ethische Herausforderungen. 
Der Onkologe 15:1004-1014
33. Ludwig, W-D (2012) Möglichkeiten und Grenzen der stratifizierenden Medizin am Beispiel von 
prädiktiven Biomarkern und “zielgerichteten” medikamentösen Therapien in der Onkologie. Zeitschrift 
für Evidenz, Fortbildung und Qualität im Gesundheitswesen 122:11-22
34. Marshall, E (2011) Waiting for the revolution. Science 331:526-529
35. McDermott, U; Downing, JR; Stratton, MR (2011) Genomics and the continuum of cancer care. New 
England Journal of Medicine 364:340-350
36. Mirnezami, R; Nicholson, J; Darzi, A (2012) Preparing for precision medicine. New England Journal 
of Medicine 366:489-491
37. Phimister, EG; Feero, GW; Guttmacher, AE (2012) Realizing genomic medicine. New England Journal 
of Medicine 366:757-759
38. Rauprich, O (2010) Rationierung unter den Bedingungen der Endlichkeit im Gesundheitswesen, 
Endliches Leben Interdisziplinäre Zugänge zum Phänomen der Krankheit. Hg. G Thomas; M Höfner; 
S Schaede. Tübingen: Mohr Siebeck, 229-256
39. Richter-Kuhlmann, E (2012a) Pränataldiagnostik: Paradigmenwechsel. Deutsches Ärzteblatt 109:A-
1306
40. Richter-Kuhlmann, EA (2012b) Gesundheitssurvey des Robert-Koch-Instituts: Zivilisationskrankheiten 
nehmen zu. Deutsches Ärzteblatt 109:C-1171-1172
41. Schulze, M (2011) Programme of the international symposium: predictive genetic testing, risk 
communication and risk perception: Value of genetic. Information for diabetes risk prediction. Berlin: 
Robert Koch Institut
42. Schwan, S (2013) Die Dividendenhoffnungen bleiben intakt. Frankfurter Allgemeine Zeitung, 
14.01.2013
43. Siegmund-Schultze, N (2011) Versorgung von Krebspatienten: Menschliche Zuwendung aufwerten. 
Deutsches Ärzteblatt 108:A-932
44. Simmons, RK; Echouff o-Tcheugui, JB; Sharp, SJ et al. (2012) Screening for type 2 diabetes and 
population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. 
Lancet 380:1741-1748 
45. Sledge, GW (2012) The challenge and promise of the genomic era. Journal of Clinical Oncology 30:203-
209
46. Tauber, AI; Sarkar, S (1993) The ideology of the human genome project. Journal of the Royal Society 
and Medicine 86:537–540
47. Valachis, A; Polyzos, NP; Nearchou, A et al. (2012) Financial relationships in economic analyses of 
targeted therapies in oncology. Journal of Clinical Oncology 30:1316-1320
48. Vollmann, J (2008) Patientenselbstbestimmung und Selbstbestimmungsfähigkeit: Beiträge zur klinischen 
Ethik. Stuttgart: Kohlhammer
49. Vollmann, J; Schildmann, J; Kohnen, T (2011) Onkologie: Sehr gut recherchiert. Deutsches Ärzteblatt 
108:A-2341
50. Yurkiewicz, S (2010) The prospects for personalized medicine. Hastings Center Report 40:14-18
266
JAHR  Vol. 6/2  No. 12  2015
Jochen Vollmann
Personalizirana medicina: postavljanje 
prioriteta i oportunitetni troškovi u 
europskim sustavima javnog zdravstva
SAŽETAK
“Personalizirana medicina” trenutno privlači veliku pozornost i podiže velike nade i očekivanja 
u modernoj medicini. Pojam “personalizirane medicine” označava korištenje genetskih ili 
drugih informacija biomarkera i time se udaljava od osobnog odnosa liječnik - pacijent. 
Nadalje, personalizirana medicina povezana je s etičkim problemima kao što su određivanje 
prioriteta i oportunitetni troškovi u sustavima javnog zdravstva utemeljenim na solidarnosti. 
Personalizirana medicina nudi moderne, vrlo specifične i skupe dijagnostike i liječenja, 
koja su korisna samo ograničenim podskupinama bolesnika. Istovremeno, istraživanja u 
drugim područjima kliničke medicine, koja bi mogla biti korisna svim bolesnicima,i dalje se 
nedovoljno financiraju.
Ključne riječi: personalizirana medicina, osoba, određivanje prioriteta, oportunitetni 
troškovi, ekonomija zdravlja
